News

June 3, 2011
čára

NTC logo

The logotype of our subsidiary National Tissue Center, a.s., which will be located on the Campus science and business park building in Bohunice from the end of June, represents the support our company will provide to our scientific partners and institutes during the market application and transfer of technologies in the Brno region.

May 28, 2011
čára

The Economy of healthcare congress

During the period of 10th – 13th June 2011, the world congress on the Economy of healthcare held in Toronto will publish a study in the field of modern therapy comparing the treatment of damaged knee cartilage by the newest method of implanting one’s own cultivated cartilage cells to the current surgical orthopedic treatment. The comparison will include an economical evaluation of medical expenses for individual treatments. The results of the study show that the modern method of implanting one's own cultivated cartilage cells seems to be more economical than conventional treatment.

This modern treatment is available in the Czech Republic via the Chondrograft 1000 and Chondrograft 2000 preparations.

May 25, 2011
čára

Innovations in transplantology save patients

The first and second complete facial transplant has been performed by MUDr. Bohdanem Pomahačem, the head of the Plastic Surgery Clinic at the Brigham and Women's Hospital in Boston (www.brighamandwomens.org). The surgery has shown that conventional transplantology is still a highly innovational field of medicine. This can also be seen in the first successful sternum reconstruction from bone allotransplants performed last year in University Hospital Olomouc in cooperation with the tissue institution at University Hospital Brno.

May 20, 2011
čára

Installation of unique technologies

An isolator line and large-capacity clean areas were installed as part of the new center for development and production of modern therapy products. The technology will be used for the production of implants from one’s own as well as allogeneic cells of patients.

May 4, 2011
čára

3rd nationwide conference BIOIMPLANTOLOGY 2011

University Hospital Brno, National Tissue Center a.s. and the Society for Bioimplantology ČLS JEP, represented by MUDr. Roman Kraus, MBA, UHB director and MUDr. Pavel Březovský, CSc., MBA, director of the Transplantation Coordination Center, have held the 3rd nationwide conference called BIOIMPLANTOLOGY 2011.

read more >>

May 3, 2011
čára

A unique center for high-quality medicine is being built in Ostrava

Representatives of PrimeCell, a.s., National Tissue Center, a.s., and University Hospital Ostrava have successfully passed consultation in the National Institute for Drug Control regarding the new scientific-technical park called 4 MEDI in Ostrava. The center will be designated for high-capacity production of high-quality products for modern therapy and cell transplants.

May 2, 2011
čára

NTC bio medical center

PrimeCell is preparing for the commencement of operation of the bio medical center in Campus Science and Business park in Brno, at Palach square in Bohunice. The grand opening will occur between 28th – 30th June.

April 22, 2011
čára

The senate has approved new rules for modern therapy

The senate has approved the appropriate novelization of the law on drugs in May, fulfilling EU directives regarding the ensuring of quality, efficiency and safety of preparations for modern therapy; i.e. medical preparations for genetic and somato-cellular therapy and preparations of tissue engineering.

April 19, 2011
čára

Top-notch results of Czech research and medicine

National Tissue Center, a.s., was the co-host of the „Bioimplantologie 2011“ conference. The event had high participation and introduced the newest results of Czech and Slovak doctors and researchers in the field of modern therapy, biotechnology and material engineering.

March 17, 2011
čára

Hope for Patients

A significant event in the biotechnology field, the Bio Europe Spring 2011 conference held this year in Milan, opened new pathways for mutual business cooperation and developing the field. PrimeCell made a number of valuable agreements in the area of stem cell treatments, supporting our goal of making treatment available to a broader group of patients in the future.

March 16, 2011
čára

New Research Partner

PrimeCell has expanded its innovation and development partner network to include the Faculty of Biomedical Engineering at Czech Technical University in Prague and a team headed by Prof. Miroslav Jelínek, DrSc. Cooperation will continue in layering tissue carriers for tissue engineering applications. The research partner network takes in more than 50 public institutions, universities and private firms in all.

January 15, 2011
čára

We fulfil the visions of modern medicine

In implementing projects, the Primecell Group provides important support for investment in science and research in the Czech Republic. This year, PrimeCell R&D Group development and investment projects accounted for an astounding volume of more than €40 million.

<< previous 1 19 20 21 22 
23

 

PrimeCell Therapeutics a.s. je biotechnologická společnost vyvíjející léčivé přípravky z lidských buněk s cílem zlepšit kvalitu lidského života. Využíváme přirozené léčivé a regenerativní vlastnosti buněk. Speciálními manipulacemi ovlivňujeme vlastnosti buněk tak, aby léčebného účinku bylo dosaženo v postižených tkáních.

 

 

Využíváme přirozených léčivých a regenerativních vlastností buněk a jejich součástí. Speciálními ověřenými postupy ovlivňujeme vlastnosti buněk tak, abychom dosáhli léčebného účinku v postižených tkáních.

PrimeCell Therapeutics a.s. poskytuje pacientům nové metody vysoce personalizované efektivní léčby, které využívají lidské buňky a tkáně a to především v případech, kdy stav pacientů nelze léčit běžnými léčivy nebo jinou konvenční metodou, či je-li léčba lidskými buňkami pro pacienta šetrnější. Bude se věnovat především přípravě autologních a alogenních léčivých přípravků pro ortopedické indikace, ischemické choroby, kožní defekty nebo hojení ran.

 

Jedním ze základů aktivit PrimeCell Therapeutics a.s je intenzivní spolupráce s renomovanými tuzemskými a světovými vědeckými institucemi a klinickými centry s cílem využít výsledky základního výzkumu v klinické praxi, a to co nejrychleji ku prospěchu pacientů. Dále bude rozvíjena dosavadní síť více než sto klinických center a partnerů v České republice a v zahraničí.

 

PrimeCell Therapeutics a.s. byl založen v roce 2007. Je jedním z nejvýznamnějších investorů v Evropě v oblasti regenerativní medicíny. Vlastní a provozuje vysoce moderní vývojovou a výrobní infrastrukturu pro aplikovaný vývoj, zpracování a výrobu lidských buněk a tkání. Ve svém portfoliu má téměř 8000 m2 laboratorních prostor, z toho 2000 m2 cGMP zázemí pro vývoj a výrobu buněčných a tkáňových produktů. Více o infrastruktuře PrimeCell Therapeutics a.s. naleznete na www.natic.cz a www.4medi.cz

 

  About us
who we are
corporate Overview executive
and non-executive

directors
our history
partnerships and our
responsibility
Advanced & Cell Therapy

Key programs & products
current products
products in the pipeline
stories
Research
our innovative strategy
research areas
our developments
co-operation opportunites
Media
news
PrimeCell in media
odborné publikace
photogallery
corporate identity
About 4MEDi

Contact us
contact us
informace pro akcionáře
PrimeCell Therapeutics a.s.
Sídlo: Jáchymova 26/2 Praha 1/ 110 00
Office: U Plynárny 1002/97 Praha 10/ 101 00

Praha / Brno / Ostrava / New York / Singapore / Jeddah
© by primecell | pupečníková krev | design by upsala